Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Evangelos Terpos, MD PhD, Despina Fotiou, MD, Konstantinos Anargyrou, MD, Theodoros P. Vassilakopoulos, MD PhD, Dimitrios Christoulas, MD, Polyzois Makras, MD PhD, Maria Dimou, MD PhD, Ioannis Ntanasis-Stathopoulos, MD, Stavroula Masouridou, MD, Maria K. Angelopoulou, MD, Athanasios Papatheodorou, PhD, Konstantinos Tsionos, MD, Panayiotis Panayiotidis, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4124.

https://doi.org/10.1182/blood-2019-123615

Published: 2019

Journal Articles

Long Acting Zoledronic Acid Treatment for Vertebral Fracture Prevention in Multipl Myeloma Patients with Osteoporosis

Murat Cinarsoy, Ahmet Kursad Gunes, Hilmi Erdem Gozden

Blood (2018) 132 (Supplement 1): 1954.

https://doi.org/10.1182/blood-2018-99-111133

Published: 2018

Journal Articles

Common Link between Bone and Heart Health in Thalassemia Major

Antonella Meloni, PhD, Cristina Vassalle, Laura Pistoia, MD, Silvia Maffei, Massimo Allò, Crocetta Argento, Alessandra Spiga, Luciana Rigoli, Maria Flavia Fiorenza, Aurelio Maggio, MD, Angelica Barone, Vincenzo Positano, Alessia Pepe, MD

Blood (2017) 130 (Supplement 1): 4763.

https://doi.org/10.1182/blood.V130.Suppl_1.4763.4763

Published: 2017

Journal Articles

Pancreatic Iron and Bone Health in Thalassemia Major

Antonella Meloni, PhD, Silvia Maffei, Laura Pistoia, MD, Cristina Vassalle, Maria Caterina Putti, MD, Angelo Peluso, MD, Calogera Gerardi, MD, Cristina Paci, Elena Facchini, Maria Grazia Sanna, Aurelio Maggio, MD, Vincenzo Positano, Alessia Pepe, MD

Blood (2017) 130 (Supplement 1): 4765.

https://doi.org/10.1182/blood.V130.Suppl_1.4765.4765

Published: 2017

Journal Articles

Yearly Long-Acting Zoledronic Acid (Reclast) Is Safe and Effective for Treatment of Bone Loss after Hematopoietic Stem Cell Transplantation

Zhuoyan Li, MD, Samuel M Rubinstein, MD, Carey Clifton, ACNP, Leigh Ann Vaughan, ACNP, Melissa Logue, ACNP, Michael T. Byrne, DO, Adetola A. Kassim, MD MS, Brian G Engelhardt, MD, Wichai Chinratanalab, MD, Salyka Sengsayadeth, MD, Stephen J. Brandt, MD, Stacey A. Goodman, MD MS, John P. Greer, MD, Madan Jagasia, MD, Bipin N. Savani, MD

Blood (2016) 128 (22): 3438.

https://doi.org/10.1182/blood.V128.22.3438.3438

Published: 2016

Journal Articles

Bone Mineral Density Utilization in Patients with Newly Diagnosed Multiple Myeloma: A Single Center Experience

Eli Muchtar, MD, Adi Zelig, Eyal Robenshtok, MD, Tzippy Shochat, MSc, Nino Oniashvili, PhD, Irina Amitai, MD, Pia Raanani, MD, Hila Magen, MD

Blood (2015) 126 (23): 5386.

https://doi.org/10.1182/blood.V126.23.5386.5386

Published: 2015

Journal Articles

The Role of RANKL/Osteoprotegerin and Wnt Signaling Pathways in the Development of Osteoporosis in Patients with Hemophilia

Panagiotis Anagnostis, Sofia Vakalopoulou, Dimitrios Christoulas, Spyridon Karras, Athanasios Papatheodorou, Eirini Katodritou, Panagiotis Kokkoris, Vasilia Garipidou, Evangelos Terpos

Blood (2015) 126 (23): 2284.

https://doi.org/10.1182/blood.V126.23.2284.2284

Published: 2015

Journal Articles

Fracture Prevalence in Adults with Transfusion-Dependent Thalassemia Is Related to Osteoporosis and Age

John C. Chapin, MD, Maria Vogiatzi, MD, Dorothy Kleinert, NP, Ersilia DeFilippis, Paul Christos, DrPH, Patricia Giardina, MD

Blood (2014) 124 (21): 4902.

https://doi.org/10.1182/blood.V124.21.4902.4902

Published: 2014

Journal Articles

Circulating Periostin Is Elevated In Patients With Hemoglobinopathies and Correlates With Bone Mineral Density In Double Heterozygous Sickle-Cell/Beta-Thalassemia Patients; A Novel Marker Of Bone Strength?

Ersi Voskaridou, Dimitrios Christoulas, Athanasios Papatheodorou, Panagiotis Oikonomopoulos, Veroniki Komninaka, Konstantina Repa, Evangelos Terpos

Blood (2013) 122 (21): 3445.

https://doi.org/10.1182/blood.V122.21.3445.3445

Published: 2013

Journal Articles

Growth Hormone – Insulin-Like Growth Factor –I (IGF-I) Axis and Bone Mineral Density In Adults With Thalassemia Major (TM)

Mohamed A. Yassin, MBBS, MSc, CABM, FACP, Ashraf T Soliman, MD FRCP PhD, Vincenzo Desanctis, MD

Blood (2013) 122 (21): 1021.

https://doi.org/10.1182/blood.V122.21.1021.1021

Published: 2013

Journal Articles

Circulating Activin-A Is Elevated in Patients with Thalassemia Major and Double Heterozygous Sickle-Cell/Beta-Thalassemia and Correlates with Markers of Hemolysis and Bone Mineral Density

Ersi Voskaridou, Dimitrios Christoulas, Maria Dimopoulou, Veroniki Komninaka, Maria Tsalkani, Athanasios Papatheodorou, Evangelos Terpos

Blood (2012) 120 (21): 3256.

https://doi.org/10.1182/blood.V120.21.3256.3256

Published: 2012

Journal Articles

Effects of Anti Rank Ligand Denusomab On Beta Thalassmia Major Induced Osteoporosis.

Mohamed A. Yassin, MBBS, MSc, CABM, FACP, Ashraf T Soliman, MD, FRCP, PhD, Mohamed Osman, MD, Hanadi Rafii El-Ayoubi, MD, Ahmed S Elawwa, MD, Vincenzo Desanctis, MD

Blood (2012) 120 (21): 2121.

https://doi.org/10.1182/blood.V120.21.2121.2121

Published: 2012

Journal Articles

Intermittent Zolendronic Acid (ZA) for the Prevention of Osteoporosis After Allogeneic Hematopoietic Cell Transplantation (HCT)

Parameswaran Hari, MBBS, MD, MRCP, Todd E. Defor, MS, David H. Vesole, MD, PhD, Christopher Bredeson, MD, MSc, FRCPC, Linda J Burns, MD

Blood (2012) 120 (21): 1965.

https://doi.org/10.1182/blood.V120.21.1965.1965

Published: 2012

Journal Articles

Bone Involvement in Patients with Non-Neuronopathic Gaucher Disease Is Characterized by Increased Osteoclast Function Partially Due to High Circulating C-C Motif Ligand 3,

Veroniki Komninaka, Theodore Marinakis, Dimitrios Christoulas, Konstantina Repa, Dionysia Kolomodi, Maria Mitropoulou, Maria Gkotzamanidou, Athanasios Papatheodorou, Nikolaos Anagnostopoulos, Meletios Athanasios Dimopoulos, MD, Evangelos Terpos

Blood (2011) 118 (21): 3215.

https://doi.org/10.1182/blood.V118.21.3215.3215

Published: 2011

Journal Articles

Effects of Long Term Imatinib on Bone Mineral Density In Patients with Chronic Myelogenous Leukemia (CML) or Gastrointestinal Stromal Tumor (GIST)

Ellin Berman, MD, Robert Maki, MD, PhD, Azeez Farooki, MD, Monica Girotra, MD, Suzanne Chanel, RN, Catherine Cheng, BA, H. William Strauss, MD, Martin Fleisher, PhD

Blood (2010) 116 (21): 2276.

https://doi.org/10.1182/blood.V116.21.2276.2276

Published: 2010

Journal Articles

Influence of Chronic Therapies on Bone Mineral Density In Children with Sickle Cell Anemia.

Elizabeth Walsh, MD, Yaw Appiagyei-Dankah, MD, Myla Ebeling, Thomas Hulsey, Ram Kalpatthi, MD

Blood (2010) 116 (21): 1650.

https://doi.org/10.1182/blood.V116.21.1650.1650

Published: 2010

Journal Articles

Low Bone Mineral Density and High Bone Turnover In Patients with Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study

Konstantinos Anargyrou, Theodoros P. Vassilakopoulos, Konstantinos Tsionos, Panayiotis Kokkoris, Georgios Boutsikas, Maria K. Angelopoulou, Dimitrios Christoulas, Stavroula Masouridou, Maria Dimou, Athanasios Papatheodorou, Danos N. Chatzifotiadis, Panayiotis Panayiotidis, Gerasimos A. Pangalis, Photis Beris, Evangelos Terpos

Blood (2010) 116 (21): 5071.

https://doi.org/10.1182/blood.V116.21.5071.5071

Published: 2010

Journal Articles

Bone Mineral Density Changes In Patients with Paraproteinemia After Treatment with Bortezomib

Tamara Berno, Kenneth Boucher, PhD, Fenghuang Zhan, MD, PhD, Guido J. Tricot, MD, PhD, Benjamin Mughal, BS, Maurizio Zangari, MD

Blood (2010) 116 (21): 4989.

https://doi.org/10.1182/blood.V116.21.4989.4989

Published: 2010

Journal Articles

High Circulating Levels of Sclerostin Correlate with Bone Mineral Density In Patients with Thalassemia and Osteoporosis: The Role of the Wnt Signaling In the Pathogenesis of Bone Loss In Thalassemia

Ersi Voskaridou, Dimitrios Christoulas, Athanasios Papatheodorou, Cornelia Bratengeier, Eleni Plata, Despoina Kaliontzi, Wolfgang Woloszczuk, Evangelos Terpos

Blood (2010) 116 (21): 1010.

https://doi.org/10.1182/blood.V116.21.1010.1010

Published: 2010

Journal Articles

Neridronate (NE) for the Treatment of Osteoporosis In Patients with β-Thalassemia: Results from an Italian Multicenter Randomized, Open Label, Phase II Trial

Gian Luca Forni, MD, Silverio Perrotta, MD, Caterina Borgna Pignatti, MD, Domenico Giuseppe D'Ascola, MD, Bruno Nobili, MD, Lorella Pitrolo, MD, Giovanni Quarta, MD, Paolo Rigano, MD, Laura Zanaboni, MD, Ernesto Palummeri, MD

Blood (2010) 116 (21): 4282.

https://doi.org/10.1182/blood.V116.21.4282.4282

Published: 2010

NARROW

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Long Acting Zoledronic Acid Treatment for Vertebral Fracture Prevention in Multipl Myeloma Patients with Osteoporosis

Common Link between Bone and Heart Health in Thalassemia Major

Pancreatic Iron and Bone Health in Thalassemia Major

Yearly Long-Acting Zoledronic Acid (Reclast) Is Safe and Effective for Treatment of Bone Loss after Hematopoietic Stem Cell Transplantation

Bone Mineral Density Utilization in Patients with Newly Diagnosed Multiple Myeloma: A Single Center Experience

The Role of RANKL/Osteoprotegerin and Wnt Signaling Pathways in the Development of Osteoporosis in Patients with Hemophilia

Fracture Prevalence in Adults with Transfusion-Dependent Thalassemia Is Related to Osteoporosis and Age

Circulating Periostin Is Elevated In Patients With Hemoglobinopathies and Correlates With Bone Mineral Density In Double Heterozygous Sickle-Cell/Beta-Thalassemia Patients; A Novel Marker Of Bone Strength?

Growth Hormone – Insulin-Like Growth Factor –I (IGF-I) Axis and Bone Mineral Density In Adults With Thalassemia Major (TM)

Circulating Activin-A Is Elevated in Patients with Thalassemia Major and Double Heterozygous Sickle-Cell/Beta-Thalassemia and Correlates with Markers of Hemolysis and Bone Mineral Density

Effects of Anti Rank Ligand Denusomab On Beta Thalassmia Major Induced Osteoporosis.

Intermittent Zolendronic Acid (ZA) for the Prevention of Osteoporosis After Allogeneic Hematopoietic Cell Transplantation (HCT)

Bone Involvement in Patients with Non-Neuronopathic Gaucher Disease Is Characterized by Increased Osteoclast Function Partially Due to High Circulating C-C Motif Ligand 3,

Effects of Long Term Imatinib on Bone Mineral Density In Patients with Chronic Myelogenous Leukemia (CML) or Gastrointestinal Stromal Tumor (GIST)

Influence of Chronic Therapies on Bone Mineral Density In Children with Sickle Cell Anemia.

Low Bone Mineral Density and High Bone Turnover In Patients with Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study

Bone Mineral Density Changes In Patients with Paraproteinemia After Treatment with Bortezomib

High Circulating Levels of Sclerostin Correlate with Bone Mineral Density In Patients with Thalassemia and Osteoporosis: The Role of the Wnt Signaling In the Pathogenesis of Bone Loss In Thalassemia

Neridronate (NE) for the Treatment of Osteoporosis In Patients with β-Thalassemia: Results from an Italian Multicenter Randomized, Open Label, Phase II Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only